• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4: A Kathy Schaefer disposed of $256 worth of Ordinary Shares (675 units at $0.38), decreasing direct ownership by 3% to 22,934 units

    4/5/21 4:24:38 PM ET
    $MNK
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MNK alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
    1. Name and Address of Reporting Person*
    Schaefer Kathy A

    (Last) (First) (Middle)
    675 MCDONNELL BLVD.

    (Street)
    HAZELWOOD MO 63042

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Mallinckrodt plc [ MNKKQ ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    Sr. VP Fin & Corp. Controller
    3. Date of Earliest Transaction (Month/Day/Year)
    04/01/2021
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Ordinary Shares 04/01/2021 F 277 D $0.38 23,332 D
    Ordinary Shares 04/02/2021 F 398 D $0.38 22,934 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    Remarks:
    /s/ Stephanie D. Miller, Attorney-in-Fact 04/05/2021
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $MNK alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MNK

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $MNK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4: Norton David Y sold $1,334 worth of Ordinary Shares (5,080 units at $0.26), closing all direct ownership in the company

    4 - Mallinckrodt plc (0001567892) (Issuer)

    8/9/21 9:09:30 AM ET
    $MNK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4: O'Neill Hugh M. sold $537 worth of Ordinary Shares (2,100 units at $0.26), decreasing direct ownership by 3% to 76,856 units

    4 - Mallinckrodt plc (0001567892) (Issuer)

    8/9/21 9:10:08 AM ET
    $MNK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4: A Kathy Schaefer disposed of $256 worth of Ordinary Shares (675 units at $0.38), decreasing direct ownership by 3% to 22,934 units

    4 - Mallinckrodt plc (0001567892) (Issuer)

    4/5/21 4:24:38 PM ET
    $MNK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MNK
    SEC Filings

    View All

    Mallinckrodt plc filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Mallinckrodt plc (0001567892) (Filer)

    11/5/21 6:01:46 AM ET
    $MNK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Mallinckrodt plc filed SEC Form 8-K: Leadership Update

    8-K - Mallinckrodt plc (0001567892) (Filer)

    11/3/21 4:31:03 PM ET
    $MNK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Mallinckrodt plc

    10-Q - Mallinckrodt plc (0001567892) (Filer)

    11/2/21 6:43:01 AM ET
    $MNK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MNK
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Mallinckrodt Receives Court Approval for "First Day" Motions to Support Ongoing Operations

    Continuing to Serve Customers and Deliver High-Quality Therapies to Patients Without Interruption; Vendors and Suppliers to be Paid in Full in the Ordinary Course DUBLIN, Aug. 30, 2023 /PRNewswire/ -- Mallinckrodt plc (OTC:MNKTQ) ("Mallinckrodt" or the "Company"), a global specialty pharmaceutical company, today announced that it has received approvals from the U.S. Bankruptcy Court for the District of Delaware for its "First Day" motions related to the Company's voluntary Chapter 11 petitions filed on August 28, 2023. As expected, the Court granted Mallinckrodt approval to ac

    8/30/23 11:54:00 AM ET
    $MNK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Mallinckrodt plc Takes Next Step to Implement Comprehensive Financial Restructuring Plan to Address Long-Term Debt and Opioid Obligations

    Initiates Voluntary Prepackaged Chapter 11 Proceedings with Overwhelming Support of Key Stakeholders, Including 85%+ of First and Second Lien Debtholders Continuing to Operate Normally, Serve Customers and Deliver High-Quality Therapies to Patients Vendors and Suppliers Expected to be Paid in Full in the Ordinary Course DUBLIN, Aug. 28, 2023 /PRNewswire/ -- Mallinckrodt plc (NYSE:MNK) ("Mallinckrodt" or the "Company"), a global specialty pharmaceutical company, today announced that it has taken the next step to implement the comprehensive financial restructuring plan contemplated by a Restructuring Support Agreement ("RSA") the Company previously entered into with more than 85% of each of th

    8/28/23 12:17:00 AM ET
    $MNK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Mallinckrodt plc Enters into Restructuring Support Agreement with Key Stakeholders on the Terms of a Prepackaged Financial Restructuring Plan

    Agreement Supported by a Substantial Majority of Each of its First and Second Lien Debtholders and Opioid Trust Financial Restructuring Plan to Significantly Reduce Debt, Increase Free Cash Flow Generation, Extend Maturity Runway and Better Position Company for Long-Term Success  Intends to Initiate Voluntary Prepackaged Chapter 11 Proceedings to Implement Plan Continuing to Deliver High-Quality Therapies to Patients and Serve Customers; Vendors and Suppliers to be Paid in Full in the Ordinary Course DUBLIN, Aug. 23, 2023 /PRNewswire/ -- Mallinckrodt plc (NYSE:MNK) ("Mallinckrodt" or the "Company"), a global specialty pharmaceutical company, today announced it has entered into a Restructur

    8/23/23 8:22:00 AM ET
    $MNK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MNK
    Leadership Updates

    Live Leadership Updates

    View All

    Mallinckrodt Announces Appointment of Dr. Peter Richardson, MRCP, as Chief Scientific Officer

    DUBLIN, Jan. 12, 2023 /PRNewswire/ -- Mallinckrodt plc (NYSE:MNK) ("Mallinckrodt" or the "Company"), a global specialty pharmaceutical company, today announced that Dr. Peter Richardson, B.Med.Sci., BM, BS, MRCP (UK) has been appointed Executive Vice President and Chief Scientific Officer, effective January 12, 2023. With more than 30 years of research and development experience in the pharmaceutical industry, Dr. Richardson will have executive responsibility for Mallinckrodt's branded research and development (R&D), medical affairs, safety, and regulatory affairs functions. He will serve on the Company's Executive Committee and succeeds Steven Romano, M.D., who departed Mallinckrodt in Dece

    1/12/23 6:45:00 AM ET
    $MNK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MNK
    Financials

    Live finance-specific insights

    View All

    Mallinckrodt plc Reports First Quarter 2023 Financial Results and Reaffirms Full Year Guidance

    Advanced Launch of Terlivaz® with Rapid and Successful Uptake in Hospital Formulary Access and Continued Medical Community Interest Reports First Quarter Net Sales of $424.6 Million; Net Loss of $249.3 Million; Adjusted EBITDA of $123.5 Million; Diluted Loss Per Share of $18.93 and Adjusted Diluted Earnings Per Share of $1.68 Increased Cash on Hand to $480.0 Million and Reduced Exposure to Interest Rate Volatility Through Interest Rate Cap Agreement, Demonstrating Ongoing Focus on Disciplined Balance Sheet Management Reaffirmed 2023 Net Sales and Adjusted EBITDA Guidance Conference Call and Webcast Today at 8:30 a.m. ET DUBLIN, May 9, 2023 /PRNewswire/ -- Mallinckrodt plc (NYSE:MNK) ("Malli

    5/9/23 6:45:00 AM ET
    $MNK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Mallinckrodt to Report Earnings Results for First Quarter 2023

    DUBLIN, April 24, 2023 /PRNewswire/ -- Mallinckrodt plc (NYSE:MNK), a global specialty pharmaceutical company, today announced that it will report first quarter 2023 earnings results for the period ended March 31, 2023, on Tuesday, May 9, 2023.  A conference call for investors will begin at 8:30 a.m. ET. The call can be accessed as follows: Live Call Participant Registration (including dial-in): https://register.vevent.com/register/BIbe1f9805fe5b4490acd8359f7bdd616dAudio Only Webcast Link (live and replay):https://edge.media-server.com/mmc/p/24fqexpxAt the Mallinckrodt website

    4/24/23 6:45:00 AM ET
    $MNK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Mallinckrodt plc Reports Fourth Quarter and Fiscal 2022 Financial Results and Provides 2023 Guidance

    Made Solid Progress on Launch of Terlivaz® with Significant Medical Community Interest Appointed Chief Scientific Officer with Proven Record of Executing Clinical Programs and Advancing Product Development Pipelines Increased Cash on Hand to $409.5 Million, Underscoring Commitment to Strengthening Balance Sheet and Disciplined Approach to Cost Management Fiscal 2023 Guidance for Adjusted EBITDA is $510 Million to $560 Million Conference Call and Webcast Today at 8:30 a.m. ET DUBLIN, Feb. 28, 2023 /PRNewswire/ -- Mallinckrodt plc (NYSE:MNK) ("Mallinckrodt" or the "Company"), a global specialty pharmaceutical company, today reported results for the fourth quarter ended December 30, 2022. 

    2/28/23 6:45:00 AM ET
    $MNK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MNK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D/A filed by Mallinckrodt plc (Amendment)

    SC 13D/A - Mallinckrodt plc (0001567892) (Subject)

    11/12/21 2:55:13 PM ET
    $MNK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by Mallinckrodt plc (Amendment)

    SC 13D/A - Mallinckrodt plc (0001567892) (Subject)

    11/5/21 2:58:50 PM ET
    $MNK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by Mallinckrodt plc (Amendment)

    SC 13D/A - Mallinckrodt plc (0001567892) (Subject)

    10/22/21 4:48:46 PM ET
    $MNK
    Biotechnology: Pharmaceutical Preparations
    Health Care